






Figure 1

RNA-polymerase inhibitors




Remdesivir (GS-5734)

MoA - prodrug converts to GS-441524
inhibits action of RNA polymerase
COVID-19 trial? - YES
Route - IV




Galidesivir (BCX-4430)

MoA - Viral RNA-polymerase binder
COVID-19-trial? - YES
Route - IV/PO



Camostat


MoA - Transmembrane
protease, serine 2 (TMPRSS2)
inhibitor
COVID-19-trial? - YES
Route - PO



Favipiravir (T-705)

MoA - prodrug, selective viral
RNA-polymerase inhibitor
COVID-19 trial? - YES
Route - PO

HIV protease inhibitors



Darunavir/Cobicistat


MoA - Combo; an HIV-1
protease inhibitor and inhibitor
of cytochrome P450 (CYP)3A
enzyme
COVID-19-trial? - YES
Route - PO

Fingolimod
MoA - sphingosine 1-
phosphate receptor
modulator
COVID-19-trial? - YES
Route - PO

Figure 2

Anti-malarials

g


**Chloroquine**

MoA - inhibits action of heme polymerase (malaria); inhibits terminal glycosylation of ACE2 (SARS-COV-2)

COVID-19-trial? - YES

Route - PO

j


**Hydroxychloroquine**

MoA - inhibits terminal glycosylation of ACE2 (SARS-COV-2)

COVID-19-trial? - YES

Route - PO

h


**Baricitinib**

MoA - JAK/NAK inhibitor, with high affinity for AAK1, a pivotal regulator of clathrin-mediated endocytosis; anti-inflammatory

COVID-19-trial? - YES

Route - PO

k



JAK
Kinase
Inhibitors


Ruxolitinib

MoA - JAK1/2 inhibitor

COVID-19-trial? - YES

Route - PO

l


**Umifenovir (Arbidol)**

MoA - Membrane haemagglutinin fusion inhibitor in influenza viruses

COVID-19-trial? - YES

Route - PO

i

**Thalidomide**

MoA - not understood, inhibits production of TNF-α

COVID-19-trial? - YES

Route - PO

Figure 2 Cont.




Figure 3




Figure 4




Figure 5

Fig. 6A




Fig. 6B




Figure 6




Figure 7




Figure 8




Figure 9